russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2026-7073PAZCIIrussjcardiol-7073Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWИндекс отношения тромбоцитов к гемоглобину (PHR) как прогностический маркер тромботических осложнений и госпитальной смертности при сердечно-сосудистых заболеваниях и перспективы его применения у пациентов на антитромботической терапииhttps://orcid.org/0000-0001-8468-6959ПостниковСергей Сергеевичclinpharm@rambler.ruhttps://orcid.org/0000-0003-4259-0945ТепловаНаталья Вадимовнаteplova.nv@yandex.ruhttps://orcid.org/0000-0002-7412-3180ГульбековаОлеся Владимировнаgulbekova1990@mail.ruhttps://orcid.org/0000-0003-3763-6646ЗариповаГульнара Рифхатовнаzaripova-g@mail.ruФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава России (Пироговский университет), ул. Островитянова, д. 1, Москва, 117997, Российская ФедерацияRussian Federation20221501202200Принято в печать70737073Copyright © Постников С.С., Теплова Н.В., Гульбекова О.В., Зарипова Г.Р., 20222022Постников С.С., Теплова Н.В., Гульбекова О.В., Зарипова Г.Р.Постников С.С., Теплова Н.В., Гульбекова О.В., Зарипова Г.Р.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/7073

Индекс отношения тромбоцитов к гемоглобину (PHR=тромбоциты ×10⁹/л/гемоглобин г/л) – предложенный в 2019-2020гг лабораторный маркер, объединяющий в едином показателе протромботический потенциал и степень анемизации пациента. Цель работы – систематизировать имеющиеся данные о патофизиологическом обосновании, методологии расчёта и прогностической значимости PHR в отношении неблагоприятных сердечно-сосудистых исходов и госпитальной смертности, а также оценить перспективы его применения для стратификации тромботического и геморрагического риска у пациентов, получающих антитромботическую терапию. В обзоре проанализированы результаты клинических исследований PHR у пациентов после чрескожного коронарного вмешательства, при остром коронарном синдроме, инфаркте миокарда с подъёмом сегмента ST, тромбоэмболии лёгочной артерии, ишемическом инсульте, а также в сосудистой хирургии и нефрологии. Показано, что повышенный PHR независимо ассоциирован с ростом общей и сердечно-сосудистой смертности и риска других неблагоприятных исходов. Рассмотрены ограничения маркера и направления дальнейших исследований.

сердечно-сосудистые заболеванияантитромботическая терапияPHRгемоглобинтромбоцитыпрогностический маркерReferencesWendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016 Apr 29;118(9):1340-7. doi: 10.1161/CIRCRESAHA.115.306841. PMID: 27126645;Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016 Apr 29;118(9):1340-7. doi: 10.1161/CIRCRESAHA.115.306841. PMID: 27126645;Li L, Geraghty OC, Mehta Z, Rotwell PM, on behalf of the Oxford Vascular study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390:490–9. 10.1016/S0140-6736(17)30770-5;Li L, Geraghty OC, Mehta Z, Rotwell PM, on behalf of the Oxford Vascular study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390:490–9. 10.1016/S0140-6736(17)30770-5;Eikelboom J.W., Connolly S.J., Bosch J., et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377: 1319–1330;Eikelboom J.W., Connolly S.J., Bosch J., et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377: 1319–1330;Bonaca M.P., Bhatt D.L., Cohen M., et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction (PEGASUS-TIMI 54). N Engl J Med. 2015;372:1791–1800;Bonaca M.P., Bhatt D.L., Cohen M., et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction (PEGASUS-TIMI 54). N Engl J Med. 2015;372:1791–1800;Chang CC, Ng AK, Kogame N, Huang PH, Kim BK, van Geuns RM. Decoding Bleeding Risks and Survival in Patients Undergoing Percutaneous Coronary Intervention on Antiplatelet Therapy. JACC Asia. 2025 Sep;5(9):1083-1094. doi: 10.1016/j.jacasi.2025.05.017. Epub 2025 Jul 29. PMID: 40736436; PMCID: PMC12426656;Chang CC, Ng AK, Kogame N, Huang PH, Kim BK, van Geuns RM. Decoding Bleeding Risks and Survival in Patients Undergoing Percutaneous Coronary Intervention on Antiplatelet Therapy. JACC Asia. 2025 Sep;5(9):1083-1094. doi: 10.1016/j.jacasi.2025.05.017. Epub 2025 Jul 29. PMID: 40736436; PMCID: PMC12426656;Bouget J. et al. Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice. PLoS ONE. 2020;15(8):e0237022. DOI: 10.1371/journal.pone.0237022;Bouget J. et al. Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice. PLoS ONE. 2020;15(8):e0237022. DOI: 10.1371/journal.pone.0237022;Staudacher D.L. et al. Triple Antithrombotic Therapy after PCI in Patients with Indication for Oral Anticoagulation. PLoS ONE. 2015. PMC4595133;Staudacher D.L. et al. Triple Antithrombotic Therapy after PCI in Patients with Indication for Oral Anticoagulation. PLoS ONE. 2015. PMC4595133;Iijima R, Ndrepepa G, Mehilli J, Bruskina O, Schulz S, Schömig A, Kastrati A. Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thromb Haemostasis. 2007;98(4):852–857;Iijima R, Ndrepepa G, Mehilli J, Bruskina O, Schulz S, Schömig A, Kastrati A. Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thromb Haemostasis. 2007;98(4):852–857;Chung I, Lip GY. Platelets and heart failure. Eur Heart J. 2006;27(22):2623–2631. doi: 10.1093/eurheartj/ehl305;Chung I, Lip GY. Platelets and heart failure. Eur Heart J. 2006;27(22):2623–2631. doi: 10.1093/eurheartj/ehl305;Pereira AA, Sarnak MJ. Anemia as a risk factor for cardiovascular disease. Kidney Int Suppl. 2003;87:S32–39. doi: 10.1046/j.1523-1755.64.s87.6.x;Pereira AA, Sarnak MJ. Anemia as a risk factor for cardiovascular disease. Kidney Int Suppl. 2003;87:S32–39. doi: 10.1046/j.1523-1755.64.s87.6.x;Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110(2):149–154. doi: 10.1161/01.CIR.0000134279.79571.73;Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110(2):149–154. doi: 10.1161/01.CIR.0000134279.79571.73;Bao K, Huang H, Huang G, Wang J, Liao Y, Pan Y, Chen W, Lu J, Yang Y, Huang Z, Chen S, Chen K, Chen L. Platelet-to-hemoglobin ratio as a valuable predictor of long-term all-cause mortality in coronary artery disease patients with congestive heart failure. BMC Cardiovasc Disord. 2021 Dec 28;21(1):618. doi: 10.1186/s12872-021-02423-6. PMID: 34961482; PMCID: PMC8714416;Bao K, Huang H, Huang G, Wang J, Liao Y, Pan Y, Chen W, Lu J, Yang Y, Huang Z, Chen S, Chen K, Chen L. Platelet-to-hemoglobin ratio as a valuable predictor of long-term all-cause mortality in coronary artery disease patients with congestive heart failure. BMC Cardiovasc Disord. 2021 Dec 28;21(1):618. doi: 10.1186/s12872-021-02423-6. PMID: 34961482; PMCID: PMC8714416;Luwen H, Yu L, Ming Y and Lei X (2025) Platelet-to-hemoglobin ratio and stroke prognosis in older adults: a nonlinear and inflammation-mediated association. Front. Med. 12:1643860. doi: 10.3389/fmed.2025.1643860;Luwen H, Yu L, Ming Y and Lei X (2025) Platelet-to-hemoglobin ratio and stroke prognosis in older adults: a nonlinear and inflammation-mediated association. Front. Med. 12:1643860. doi: 10.3389/fmed.2025.1643860;Fattizzo B, Ireland R, Dunlop A, Yallop D, Kassam S, Large J, Gandhi S, Muus P, Manogaran C, Sanchez K, Consonni D, Barcellini W, Mufti GJ, Marsh JCW, Kulasekararaj AG. Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. Leukemia. 2021 Nov;35(11):3223-3231. doi: 10.1038/s41375-021-01190-9. Epub 2021 Mar 4. PMID: 33664463; PMCID: PMC8550969;Fattizzo B, Ireland R, Dunlop A, Yallop D, Kassam S, Large J, Gandhi S, Muus P, Manogaran C, Sanchez K, Consonni D, Barcellini W, Mufti GJ, Marsh JCW, Kulasekararaj AG. Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. Leukemia. 2021 Nov;35(11):3223-3231. doi: 10.1038/s41375-021-01190-9. Epub 2021 Mar 4. PMID: 33664463; PMCID: PMC8550969;Brissot E, Troadec MB, Loréal O, Brissot P. Iron and platelets: A subtle, under-recognized relationship. Am J Hematol. 2021 Aug 1;96(8):1008-1016. doi: 10.1002/ajh.26189. Epub 2021 May 14. PMID: 33844865;Brissot E, Troadec MB, Loréal O, Brissot P. Iron and platelets: A subtle, under-recognized relationship. Am J Hematol. 2021 Aug 1;96(8):1008-1016. doi: 10.1002/ajh.26189. Epub 2021 May 14. PMID: 33844865;Zheng Y.Y. et al. Platelet-to-hemoglobin ratio as a novel predictor of long-term adverse outcomes in patients after percutaneous coronary intervention: a retrospective cohort study. Eur J Prev Cardiol. 2020;27(19):2216–2219. DOI: 10.1177/2047487319870346;Zheng Y.Y. et al. Platelet-to-hemoglobin ratio as a novel predictor of long-term adverse outcomes in patients after percutaneous coronary intervention: a retrospective cohort study. Eur J Prev Cardiol. 2020;27(19):2216–2219. DOI: 10.1177/2047487319870346;Kofos, C.; Stachteas, P.; Fyntanidou, B.; Papazoglou, A.S.; Samaras, A.; Nasoufidou, A.; Apostolopoulou, A.; Karakasis, P.; Arvanitaki, A.; Bantidos, M.G.; et al. The Platelet-to-Hemoglobin Ratio as a Prognostic Marker in Patients with Diabetes Mellitus and Acute Coronary Syndrome. J. Clin. Med. 2025, 14, 6780. https://doi.org/10.3390/jcm14196780;Kofos, C.; Stachteas, P.; Fyntanidou, B.; Papazoglou, A.S.; Samaras, A.; Nasoufidou, A.; Apostolopoulou, A.; Karakasis, P.; Arvanitaki, A.; Bantidos, M.G.; et al. The Platelet-to-Hemoglobin Ratio as a Prognostic Marker in Patients with Diabetes Mellitus and Acute Coronary Syndrome. J. Clin. Med. 2025, 14, 6780. https://doi.org/10.3390/jcm14196780;Işık F., Soner S. Platelet-to-Hemoglobin Ratio Is an Important Predictor of In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction. Cureus. 2022;14(7):e26833. PMC9375105;Işık F., Soner S. Platelet-to-Hemoglobin Ratio Is an Important Predictor of In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction. Cureus. 2022;14(7):e26833. PMC9375105;Ozbeyaz NB, Gokalp G, Gezer AE, Algul E, Sahan HF, Aydinyilmaz F, Guliyev I, Kalkan K. Novel marker for predicting the severity and prognosis of acute pulmonary embolism: platelet-to-hemoglobin ratio. Biomark Med. 2022 Aug;16(12):915-924. doi: 10.2217/bmm-2022-0201. Epub 2022 Jul 14. PMID: 35833861;Ozbeyaz NB, Gokalp G, Gezer AE, Algul E, Sahan HF, Aydinyilmaz F, Guliyev I, Kalkan K. Novel marker for predicting the severity and prognosis of acute pulmonary embolism: platelet-to-hemoglobin ratio. Biomark Med. 2022 Aug;16(12):915-924. doi: 10.2217/bmm-2022-0201. Epub 2022 Jul 14. PMID: 35833861;Işık F. et al. Platelet-hemoglobin ratio predicts amputation in patients with below-knee peripheral arterial disease. PMC. 2022. PMC933604;Işık F. et al. Platelet-hemoglobin ratio predicts amputation in patients with below-knee peripheral arterial disease. PMC. 2022. PMC933604;Zhao L, Zhang Q, Li Z, Shen Y, Huang D, Liu H, Li X, Yan Q, Li Y, Yuan Y, Xie K. Platelet-to-hemoglobin ratio as a novel prognostic biomarker in sepsis-associated AKI: a multicenter cohort study. BMC Nephrol. 2025 Nov 25;26(1):711. doi: 10.1186/s12882-025-04640-z. PMID: 41286668; PMCID: PMC12751659.Zhao L, Zhang Q, Li Z, Shen Y, Huang D, Liu H, Li X, Yan Q, Li Y, Yuan Y, Xie K. Platelet-to-hemoglobin ratio as a novel prognostic biomarker in sepsis-associated AKI: a multicenter cohort study. BMC Nephrol. 2025 Nov 25;26(1):711. doi: 10.1186/s12882-025-04640-z. PMID: 41286668; PMCID: PMC12751659.

The authors declare that there are no conflicts of interest present.